Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Jie XuLu XieXin SunKuisheng LiuXin LiangZhenyu CaiXiaodong TangWei GuoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The protracted d × 5×2 VIT schedule showed superior efficacy and favorable tolerability compared with the shorter d × 5 VIT schedule in patients with relapsed or refractory Ewing sarcoma.